Publications of Sergi Papiol
All genres
Journal Article (19)
1.
Journal Article
92, pp. 29 - 37 (2025)
Contrasting genetic burden for bipolar disorder: Early onset versus late onset in an older adult bipolar disorder sample. EUROPEAN NEUROPSYCHOPHARMACOLOGY 2.
Journal Article
370, pp. 118 - 123 (2025)
Further evidence for the association between childhood trauma and suicidal ideation in young individuals: A twin based study. JOURNAL OF AFFECTIVE DISORDERS 3.
Journal Article
136, 111161 (2025)
Sex-specific association between schizophrenia polygenic risk and subclinical schizophrenia-related traits. PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY 4.
Journal Article
Genetic Analysis of Retinal Cell Types in Neuropsychiatric Disorders. JAMA psychiatry (2025)
5.
Journal Article
90, pp. 62 - 68 (2025)
The microRNA profile of brain-derived extracellular vesicles: A promising step forward in developing pharmacodynamic biomarkers for psychiatric disorders. EUROPEAN NEUROPSYCHOPHARMACOLOGY 6.
Journal Article
96 (10), pp. 792 - 803 (2024)
Signature of Altered Retinal Microstructures and Electrophysiology in Schizophrenia Spectrum Disorders Is Associated With Disease Severity and Polygenic Risk. BIOLOGICAL PSYCHIATRY 7.
Journal Article
14 (1), 196 (2024)
Multimodal workflows optimally predict response to repetitive transcranial magnetic stimulation in patients with schizophrenia: a multisite machine learning analysis. TRANSLATIONAL PSYCHIATRY 8.
Journal Article
86, pp. 49 - 54 (2024)
Shared vulnerability and sex-dependent polygenic burden in psychotic disorders. EUROPEAN NEUROPSYCHOPHARMACOLOGY 9.
Journal Article
92, pp. 29 - 37 (2024)
Contrasting genetic burden for bipolar disorder: Early onset versus late onset in an older adult bipolar disorder sample. European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology 10.
Journal Article
67 (1), e31 (2024)
Studying the relationship between intelligence quotient and schizophrenia polygenic scores in a family design with first-episode psychosis population. EUROPEAN PSYCHIATRY 11.
Journal Article
Polygenic risk for schizophrenia converges on alternative polyadenylation as molecular mechanism underlying synaptic impairment. bioRxiv: the preprint server for biology (2024)
12.
Journal Article
11 (1), e11 (2024)
Lost and found: dynamics of relationship and employment status over time in people with affective and psychotic spectrum disorders. BJPSYCH OPEN 13.
Journal Article
15 (1), 5534 (2024)
Distinct genetic liability profiles define clinically relevant patient strata across common diseases. NATURE COMMUNICATIONS 14.
Journal Article
10 (1), p. 121 - 121 (2024)
Investigation of choroid plexus variability in schizophrenia-spectrum disorders-insights from a multimodal study. Schizophrenia (Heidelberg, Germany) 15.
Journal Article
85, pp. 23 - 31 (2024)
Lithium response in bipolar disorder: Epigenome-wide DNA methylation signatures and epigenetic aging. EUROPEAN NEUROPSYCHOPHARMACOLOGY 16.
Journal Article
Schizophrenia polygenic risk score in psychosis proneness. EUROPEAN ARCHIVES OF PSYCHIATRY AND CLINICAL NEUROSCIENCE (2023)
17.
Journal Article
53 (14), pp. 6838 - 6847 (2023)
Effect of polygenic risk score, family load of schizophrenia and exposome risk score, and their interactions, on the long-term outcome of first-episode psychosis. PSYCHOLOGICAL MEDICINE 18.
Journal Article
6 (1), 1040 (2023)
Human-specific evolutionary markers linked to foetal neurodevelopment modulate brain surface area in schizophrenia. COMMUNICATIONS BIOLOGY 19.
Journal Article
9, 284 (2019)
Polygenic burden associated to oligodendrocyte precursor cells and radial glia influences the hippocampal volume changes induced by aerobic exercise in schizophrenia patients. Translational Psychiatry Meeting Abstract (4)
20.
Meeting Abstract
87, pp. 216 - 217. World Congress of Psychiatric Genetics (WCPG), Singapore, SINGAPORE, October 15, 2024 - October 19, 2024. (2024)
EFFECTS OF POLYGENIC SCORES FOR A COMMON EXECUTIVE FUNCTION FACTOR ON THE LONGITUDINAL COURSE OF EXECUTIVE FUNCTIONS. In EUROPEAN NEUROPSYCHOPHARMACOLOGY,